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The migration of leukocytes through intersti-
tial extracellular matrices has recently received 
considerable attention. Sophisticated in vitro as-
says using fi  brous collagen matrices and three-
  dimensional investigation of leukocyte migration 
suggest a β1-integrin– and protease-independent 
mode of leukocyte movement within interstitial 
matrices (1). Although these studies are physio-
logically more relevant than studies of random 
migration on or through immobilized substrates, 
they do not refl  ect the complexity of the in vivo 
situation nor are they relevant to the specialized 
migration processes required to cross basement 
membranes (BMs). The BM is the fi  rst barrier 
encountered by emigrating leukocytes subse-
quent to penetration of the vascular endothe-
lial monolayer. Transmigration of this barrier 
remains diffi   cult to investigate in vitro and the 
most physiological studies use in vivo infl  amma-
tory models (2, 3) or intravital approaches (4).
BMs are tight assemblies of specialized ex-
tracellular matrix molecules. Together with 
the endothelial cell monolayer, the BM pres-
ents a barrier to the movement of proteins and 
cells across the blood vessel wall. Our work 
has shown that blood vessel endothelium has 
a   specialized BM characterized by the presence 
of two laminin isoforms, laminins 8 and 10 (5). 
Studies by Karnovsky et al. were the fi  rst to 
demonstrate that central nervous system (CNS) 
vessels are particularly impermeable to the 
movement of small molecules and elucidated 
the ultrastructural basis of this blood–brain bar-
rier (BBB) (6). Post-capillary venules in the 
CNS are ensheathed by a second BM known as 
the parenchymal BM, produced by the astro-
cytes and associated leptomeningeal cells (6), 
which is characterized by presence of laminins 
1 and 2 (5). A similar diff  erential expression 
of cellular receptors for extracellular matrix 
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The endothelial cell monolayer of cerebral vessels and its basement membrane (BM) are 
ensheathed by the astrocyte endfeet, the leptomeningeal cells, and their associated paren-
chymal BM, all of which contribute to establishment of the blood–brain barrier (BBB). As a 
consequence of this unique structure, leukocyte penetration of cerebral vessels is a multi-
step event. In mouse experimental autoimmune encephalomyelitis (EAE), a widely used 
central nervous system infl  ammatory model, leukocytes fi  rst penetrate the endothelial cell 
monolayer and underlying BM using integrin 𝗃1-mediated processes, but mechanisms used 
to penetrate the second barrier defi  ned by the parenchymal BM and glia limitans remain 
uninvestigated. We show here that macrophage-derived gelatinase (matrix metalloproteinase 
[MMP]-2 and MMP-9) activity is crucial for leukocyte penetration of the parenchymal BM. 
Dystroglycan, a transmembrane receptor that anchors astrocyte endfeet to the parenchymal 
BM via high affi  nity interactions with laminins 1 and 2, perlecan and agrin, is identifi  ed as 
a specifi  c substrate of MMP-2 and MMP-9. Ablation of both MMP-2 and MMP-9 in 
double knockout mice confers resistance to EAE by inhibiting dystroglycan cleavage and 
preventing leukocyte infi  ltration. This is the fi  rst description of selective in situ proteolytic 
damage of a BBB-specifi  c molecule at sites of leukocyte infi  ltration.
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  molecules at the endothelial and parenchymal borders also 
exists. In particular, dystroglycan is exclusively expressed on 
the astrocyte endfeet (5, 7, 8). Dystroglycan exists as an extra-
cellular α-subunit and a transmembrane β-subunit, which 
are products of the same gene and result from posttranslation 
processing of the molecule (9). The α-dystroglycan subunit 
is a receptor for several BM components of the parenchymal 
BM, including laminins 1 and 2, perlecan and agrin (10), as 
well as the extracellular neuronal component, neurexin (11), 
and is considered to anchor the astrocyte endfeet to the pa-
renchymal BM. Collectively, the endothelial cell layer, astro-
cyte endfeet, and their associated BMs constitute the cellular 
BBB and defects in any one of these components compro-
mises the barrier function of CNS vessels (11, 12).
Using a mouse model of experimental autoimmune 
  encephalomyelitis (EAE), we have shown that encephalito-
genic T cells interact with the endothelial BM laminins, but 
not with the parenchymal BM laminins, despite having the 
cellular receptors capable of mediating such interactions (5). 
In the course of EAE, leukocytes accumulate in the perivas-
cular space defi  ned by the inner endothelial BM and the 
outer parenchymal BM, leading to focal leukocyte accumu-
lation known as perivascular cuff  s. Clinical symptoms, how-
ever, only become apparent after leukocyte penetration of 
the parenchymal BM. These results indicate that the mecha-
nism of leukocyte transmigration of the inner endothelial 
cell BM diff  ers from that used to penetrate the parenchymal 
BM and that the latter is a disease-relevant step. A delay in 
the onset of EAE symptoms has been observed in several 
mouse strains, some of which suggest a delay in the penetra-
tion of the outer parenchymal border. These include macro-
phage-depleted mice (13), TNF-α KO mice (14), and 
L-selectin KO mice (15). In the macrophage-depleted mice, 
leukocyte transendothelial cell migration is not impeded, but 
rather defi  ciencies occur at the level of transmigration of the 
parenchymal BM and the glia limitans, supporting the con-
cept of a double barrier migration process (13). Passive trans-
fer of encephalitogenic T cells in macrophage-depleted mice 
results in T cell accumulation in the perivascular cuff  , sug-
gesting that macrophages have a primary role associated with 
penetration of the parenchymal BM and infi  ltration of the 
CNS parenchyma (13).
The initial transmigration of the endothelial monolayer 
requires expression of the adhesion molecule α4 integrin by 
leukocytes (3). Integrin α4β1 binds to vascular cell adhesion 
molecule-1 on the endothelial surface in infl  amed vessels and 
induces matrix metalloproteinase-2 (MMP-2) expression in 
encephalitogenic T cells, which has been proposed to facili-
tate transmigration of the subendothelial matrix (16). MMPs 
are a family of Zn2+-dependent endopeptidases that degrade 
extracellular matrix proteins, but also CNS proteins such as 
myelin basic protein (17), NG2 proteoglycan (18), and cyto-
kines and chemokines (19–21). MMPs are expressed during 
embryonic development and in pathological situations where 
tissue remodeling occurs. They are synthesized in an inac-
tive proform that is activated extracellularly by proteolytic 
  cleavage under the regulation of several infl  ammatory media-
tors, including cytokines and chemokines. MMPs have been 
extensively studied in multiple sclerosis and EAE, demon-
strating activity of MMP-14/MMP-2 (16) and MMP-9 (22), 
and possibly also of MMP-7 (23) and MMP-8 (24). How-
ever, whether and which MMPs aff  ect infl  ammatory cell 
  entry into the parenchyma of the CNS or demyelination 
  remains unclear. Although protease inhibitors reduce the se-
verity or delay the onset of EAE, to date no protease inhibi-
tor has been shown to completely ablate leukocyte migration 
into the perivascular space or into the brain parenchyma 
(25, 26). As a result of the hitherto lack of consideration of 
the cellular and BM barriers encountered by emigrating leu-
kocytes, it is also unclear whether the main targets of MMP 
activity are components of the endothelial cell layer or the 
parenchymal border.
The aim of this study is to defi  ne sites of protease activity 
in the course of leukocyte infi  ltration into the CNS in a 
mouse EAE model and to identify potential targets of en-
zyme activity. The study uses a combination of in situ zy-
mography and immunofl  uorescence, permitting simultaneous 
identifi  cation of sites of protease activity and endothelial and 
parenchymal BMs, as well as infi  ltrating leukocytes. The gel-
atinases MMP-2 and MMP-9 were identifi  ed as the major 
proteases active at sites of leukocyte infi  ltration into the brain 
parenchyma, subjacent to the parenchymal BM. Macro-
phages were shown to be major sources of MMP-2 and 
MMP-9, and dystroglycan, which acts to anchor astrocyte 
endfeet to the parenchymal BM, was identifi  ed as a novel 
target of this gelatinase activity. Genetic elimination of both 
MMP-2 and MMP-9 resulted in resistance to EAE and ab-
sence of both dystroglycan cleavage and leukocyte infi  ltration 
into the CNS. The data reinforce the concept that leukocyte 
transmigration of the inner endothelial and outer parenchy-
mal BMs are separate events involving distinct molecular 
mechanisms, and demonstrate that selective gelatinase activ-
ity is essential for leukocyte penetration of the outer paren-
chymal barrier. This is the fi  rst report of selective alteration of 
a molecule expressed at the BBB at sites of leukocyte pene-
tration and it introduces the possibility that control of gelati-
nase activity may restrict leukocyte infi  ltration and thereby 
block onset of EAE symptoms.
RESULTS
In situ and gel zymography
To defi  ne sites of protease activity, in situ zymography was 
performed on stage 2 and 4 EAE brain sections using either 
fl  uorescein-conjugated gelatin or collagen type IV as sub-
strates. This was combined with immunofl  uorescent staining 
with a pan-laminin antibody to identify the endothelial and 
parenchymal BMs, or with CD45 to localize sites of leuko-
cyte infi  ltration (Fig. 1, A and B). Activity was detected when 
gelatin (Fig. 1, C–F) and not collagen type IV (Fig. 1 G) was 
used as substrate, indicating gelatinase and not collagenase 
activity. Gelatinase activity was focused at sites of leukocyte 
infi  ltration into the brain parenchyma, subjacent to the JEM VOL. 203, April 17, 2006  1009
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  parenchymal BM (Fig. 1, C–F), and was abolished by the 
general MMP inhibitor, 1,10-phenanthroline (Fig. 1 H).
As no antibodies exist that recognize active gelatinases 
(MMP-2 and MMP-9) in infl  amed mouse tissues, gel zy-
mography was used to identify gelatinases present in EAE 
brains. Results revealed prominent bands at  70 and 100 kD 
in EAE but not noninfl  amed brain extracts (Fig. 1 I). Com-
parisons with rMMP standards indicated that these bands rep-
resent the pro- and active forms of MMP-9 and MMP-2, 
respectively; suggesting that the gelatinase activity observed 
in in situ zymographies was MMP-2 and MMP-9. Weaker 
zymolytic bands of higher mol wt were apparent in EAE 
brain extracts (Fig. 1 I), indicating the presence of small 
amounts of neutrophil gelatinase B–associated lipocalin 
  complexes (27).
Gelatinase substrates
As in situ zymography identifi  ed the parenchymal BM–
  astrocyte endfeet interface as the major site of MMP activity, 
investigation for MMP substrates was focused on this site. 
Immunofl  uorescence staining patterns and/or Western blots 
of extracellular matrix molecules and their cellular receptors 
(Table I) were investigated in EAE brains (stages 2 and 4). 
No change in the distribution or Western blot patterns was 
noted for most of the molecules investigated with the excep-
tion of dystroglycan.
Immunofl  uorescence staining of noninfl  amed vessels for 
β-dystroglycan and pan-laminin showed the occurrence of 
β-dystroglycan on astrocyte endfeet adjacent to the paren-
chymal BM, but not on vascular endothelium (Fig. 2, A–C). 
This pattern is clearer in infl  amed vessels where endothelial 
and parenchymal BM are separated by the perivascular cuff   
(Fig. 2, D and E). At sites of leukocyte infi  ltration, β-dystrogly-
can staining was markedly reduced or absent (Fig. 2, E and G). 
We have previously shown the absence of discontinuities in 
the immunofl  uorescent staining pattern for integrin β1 on 
the astrocyte endfeet in EAE (5), suggesting that astrocyte 
endfeet are present at sites of leukocyte infi  ltration. This was 
confi  rmed by double staining for β-dystroglycan and glial 
fi  brillary acidic protein (GFAP), as an astrocyte marker, which 
revealed no diff  erence between GFAP staining of infl  amed 
vessels that lacked β-dystroglycan staining and those that 
retained β-dystroglycan staining and had no sign of leukocyte 
infi  ltration (Fig. 2 F).
Dystroglycan binds to several parenchymal BM compo-
nents, including laminins 1 and 2, agrin and perlecan. Loss of 
laminin 2 (28) or perlecan (29) from BMs have been reported 
to lead to instability of the dystroglycan receptor complex 
and its loss from the cell membrane. Examination of diff  erent 
stage EAE brains, triple or double immunofl  uorescently 
stained for dystroglycan, CD45 and laminin 1 (Fig. 2, G–I), 
laminin 2 (not depicted), agrin (Fig. 2, J and K), or perlecan 
(Fig. 2 L) revealed no discontinuity in these parenchymal BM 
components. As the result of lack of a suitable antibody, 
neurexin (another major dystroglycan ligand) was investi-
gated only by Western blot analysis (see next paragraph). 
Figure 1.  Gelatinase activity in EAE brains. Scheme of a post-
  capillary venule, showing cell layers and endothelial and parenchymal BMs 
separated by the perivascular space (A). EAE brain sections stained for 
pan-laminin and CD45 show leukocyte accumulation in the perivascular 
space and infi  ltration into the brain parenchyma (B). In situ zymography 
coupled with pan-laminin (C–E) or CD45 (F) immunofl  uorescence reveals 
protease activity in the CNS parenchyma subjacent to the parenchymal 
BM (arrows) at sites of leukocyte infi  ltration, only when gelatin (C–F) and 
not collagen type IV (G) is used as substrate. 1,10-phenanthroline abol-
ishes gelatinase activity (H). (I) Gelatin gel zymography of healthy (C) and 
EAE brains shows proforms of MMP-9 and MMP-2 and the smaller active 
forms in EAE samples only. Higher mol wt bands are neutrophil gelatinase 
B–associated lipocalin (NGAL)–associated lipocalin complexes. rMMP-2 
and rMMP-9 are standards. C–E are the same specimen at different mag-
nifi  cations; B, C–E, and F–H are serial sections. Data represent results 
from 10 mice. Bars, 40 μm.1010  DYSTROGLYCAN AND GELATINASES IN EAE | Agrawal et al.
  Interestingly, double staining for perlecan core protein and 
pan-laminin revealed a consistently stronger staining for per-
lecan in endothelial BMs than in parenchymal BMs (Fig. 2 L). 
The absence of β-dystroglycan staining and the diff  erential 
perlecan staining in endothelial versus parenchymal BMs was 
not the result of epitope masking, as both general unmasking 
techniques and treatment with heparatinase or hyaluronidase 
did not alter this pattern.
To investigate possible proteolytic cleavage not detect-
able by immunofl  uorescence, Western blots were performed 
for agrin, laminins 1 and 2, and neurexin. Crude stage 4 EAE 
brain extracts revealed no indication of proteolytic cleavage 
of agrin, laminin 1, and neurexin (agrin shown in Fig. 2 M).
Western blot analysis of glycoprotein-enriched extracts 
from EAE and non-EAE brains revealed the intact β-dystro-
glycan molecule at 43 kD in all samples, and an additional 
30-kD cleavage fragment in EAE samples only (Fig. 3 A). 
β-dystroglycan is a transmembrane molecule that is covalently 
bound to an extracellular α-dystroglycan subunit. Western 
blot analysis of plasma membrane preparations from EAE brains 
demonstrated that the 30-kD β-dystroglycan fragment is 
  retained in the cell membrane of the astrocyte endfeet (Fig. 3 B).
No evidence of proteolytic cleavage of α-dystroglycan was 
apparent and only the intact molecule of 120 kD was de-
tected in EAE brains (Fig. 3 C); lower bands in Fig. 3 C are 
nonspecifi  c cross-reactivity of the secondary antibody with μ 
chains of endogenous IgM (abundant in infl  amed brains) as 
shown in the negative control (Fig. 3 D).
To test whether MMP-2 and/or MMP-9 were respon-
sible for cleavage of β-dystroglycan in the EAE brains, normal 
brain extracts were treated with activated rMMP-2 or rMMP-9. 
Fig. 4 A shows the presence of intact 43-kD β-dystroglycan 
and the 30-kD cleavage product in both MMP-2– and MMP-
9–treated samples, identical to those observed in EAE brains. 
As other MMPs have been implicated in EAE, the ability 
of activated rMMP-1, rMMP-7, rMMP-8, and rMMP-3 to 
cleave dystroglycan from non-EAE brains was tested. Fig. 4 B 
shows that none of these MMPs cleave dystroglycan to the 
30-kD fragment characteristic of EAE brain extracts.
Macrophages are major sources of gelatinases
Macrophages have been suggested as critical cell types in au-
toimmunity. Apart from their potential role as APC in EAE, 
macrophages have been suggested to have an additional role 
in the movement of T cells from the perivascular space into 
the brain parenchyma (13). When encephalitogenic T cells 
are adoptively transferred into macrophage-depleted mice, 
T cells accumulate in the perivascular space, but disease is not 
induced. As macrophages are also major producers of sev-
eral MMPs (30), we investigated whether macrophages can 
produce MMP-2 and MMP-9 and whether they contribute 
to the selective cleavage of dystroglycan at the parenchymal 
Table I.  Primary antibodies to extracellular matrix molecules, their receptors, and cellular markers
Molecule Antibody name/clone Used in immunofl  uorescence (IF), 
Western blot (WB), or FACS
Reference/source
Laminin α1 317 IF, WB (5)
Laminin α2 401 IF, WB (5)
Laminin α4 377 IF, WB (5)
Laminin α5 405 IF, WB (5)
Laminin γ1 3E10 IF (5)
Laminin β1 3A4 IF (5)
Pan-laminin 455 IF, WB (5)
Perlecan core C11L1, A7L6 IF, WB BD Biosciences
Brain-specifi  c neurexin Clone 17 WB BD Biosciences
Collagen IV R94.4 IF (5)
Agrin 204 IF, WB (48)
β-dystroglycan VIMSA IF, WB (49)
β-dystroglycan NCL-43DAG WB Novo Castra
α-dystroglycan IIH6 WB Upstate
β1 integrin Ha2/5 IF BD Biosciences
α6 integrin  GoH3 IF BD Biosciences
GFAP G-A-5 IF Sigma-Aldrich
CD45.2 30F11 IF, FACS BD Biosciences
CD11c N418 FACS BD Biosciences
DEC-205 NLDC-145 IF Serotec
TCRβ H57-587 IF, FACS BD Biosciences
CD11b, CD107b MAC1 (M1/70), MAC3 (M3/84) IF, FACS, FACS BD Biosciences, Serotec
GR-1 5C6 IF SerotecJEM VOL. 203, April 17, 2006  1011
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border. This involved EAE induction by myelin/oligoden-
drocyte glycoprotein (MOG) immunization in mice depleted 
of macrophages by treatment with clodronate-liposomes 
(13). Control mice were treated with PBS-liposomes or 
no liposomes.
EAE symptoms were apparent in mice treated with PBS-
containing liposomes or no liposomes by day 10 after immuni-
zation, whereas clodronate-liposome–treated mice remained 
resistant to EAE up to day 20 after MOG immunization (Fig. 
5 A). In EAE, CD45+ T cells and monocyte/macrophages 
infi  ltrate the CNS and are recovered from perfused CNS 
tissues by discontinuous density gradient centrifugation and 
quantifi  ed by FACS (31). This extravasated CD45+ popula-
tion was examined in PBS- and clodronate-liposome–treated 
mice for MAC3high/CD45high macrophages (31), MAC3high/
CD45low activated microglia (31), and TCRβ+ T cells (Table I). 
The total number of CD45+ cells recruited to the CNS in 
clodronate-treated mice at day 19 was 30% of that observed 
in PBS-treated mice at day 15 or in clodronate-treated mice 
at day 21 after MOG immunization. A signifi  cantly lower 
proportion of these CD45+ cells represented macrophages in 
the CNS of clodronate-treated mice at day 19 (13% ± 0.34), as 
compared with clodronate-treated mice at day 21 (28% ± 2.1) 
or mice treated with PBS-liposomes (32% ± 6.4) (Fig. 5 B). 
Proportions of T cells recruited to the CNS and propor-
tions of activated microglia in the CNS were,   however, 
Figure 2.  𝗃-dystroglycan loss in infl  amed vessels. Immunofl  uores-
cence for β-dystroglycan and pan-laminin reveals continuous β-dystroglycan 
staining bordering the parenchymal BM in noninfl  amed vessels (A–C) and 
loss of β-dystroglycan in infl  amed vessels only (arrows in D and E). Triple 
staining for pan-laminin with β-dystroglycan and CD45 (G–I), or agrin 
and CD45 (J and K) reveals loss of β-dystroglycan at sites of leukocyte 
infi  ltration (G and I), despite continuous pan-laminin (H) and agrin 
(J and K) staining. Double β-dystroglycan and GFAP staining 
indicates presence of astrocyte endfeet surrounding infl  amed vessels 
(arrows in F). Perlecan staining of the parenchymal BM is continuous 
around perivascular cuffs, with higher intensity staining in endothelial 
BMs (L). Western blot reveals  200 kD agrin core protein and the charac-
teristic broad mol wt smear in stage 4 EAE and noninfl  amed brains (Cont.) 
and purifi  ed agrin (M). The table summarizes immunofl  uorescence and 
Western blot data. Images are from different specimens and represent 
results from 10 mice. Bars, 40 μm.1012  DYSTROGLYCAN AND GELATINASES IN EAE | Agrawal et al.
  unaff   ected by clodronate treatment (Fig. 5 B). Previous 
  studies have shown a specifi  c reduction of the macrophage 
population in LN and spleens of clodronate-treated mice at 
day 2 after clodronate injection (32), which was confi  rmed 
here (unpublished data).
Immunofl  uorescence revealed that MAC3+ macrophages 
were abundant in perivascular cuff  s of PBS-liposome–treated 
mice, but were absent from clodronate-liposome–treated 
mice up to day 19 after MOG immunization (Fig. 5 B). 
  Reappearance of macrophages in the CNS parenchyma of 
clodronate-liposome–treated mice at day 21 coincided with 
infi  ltration of CD45+ leukocytes and appearance of clinical 
symptoms (Fig. 5 B). Infi  ltration of nonmacrophage, CD45+ 
cells was still apparent surrounding vessels in areas outside of 
the brain parenchyma; e.g., within the choroid plexus and in 
the leptomeningeal space, in the clodronate-liposome–treated 
mice (unpublished data). Immunofl  uorescent staining identi-
fi  ed these cells as T cells, DCs, and granulocytes, further 
  confi  rming that development of the immune response was 
normal and that leukocyte recruitment to the CNS was not 
impaired, despite absence of infi  ltration into the CNS paren-
chyma. Absence of a general defi  ciency in T cell activation 
was also confi  rmed by in vitro T cell proliferation studies 
performed on clodronate- and PBS-liposome–treated mice at 
day 15 and, in the case of clodronate-liposome–treated mice, 
at days 19 and 21 after MOG immunization. Antigen-  specifi  c 
(MOG 35–55) (Fig. 6 A) and anti-CD3–induced (Fig. 6 B) 
T cell proliferation showed no signifi  cant diff  erence between 
mice treated with clodronate- or PBS-liposomes. Hence, the 
data indicate that clodronate treatment specifi  cally depletes 
macrophages and does not aff  ect other leukocyte populations 
or microglia.
Gelatinase activity was not detectable in clodronate-lipo-
some–treated mice up to day 19 after MOG immunization 
by in situ (Fig. 7 A) or gel zymography (Fig. 7 B). Corre-
sponding immunofl  uorescence showed continuous β-dystro-
glycan staining surrounding post-capillary venules (Fig. 7 A) 
and Western blots revealed only intact 43-kD dystroglycan 
(Fig. 7 C). By day 21, gelatinase activity was detectable by in 
situ zymography (Fig. 7 A) and gel zymography revealed the 
presence of pro- and active MMP-2 and MMP-9 (Fig. 7 B). 
In situ zymography localized the gelatinase activity around 
post-capillary venules at sites of leukocyte penetration of the 
parenchymal border (Fig. 7 A), where β-dystroglycan stain-
ing was signifi  cantly reduced or absent (Fig. 7 A). Corre-
sponding Western blots revealed the presence of the 30-kD 
Figure 3.  In vivo 𝗃-dystroglycan cleavage. Western blots for 
β- (A and B), α-dystroglycan (C), and secondary antibody control (D). 
A and C and WGA in B are glycoprotein-enriched CNS samples; Memb. 
is a CNS membrane fraction (B). All samples are run under reducing condi-
tions. Intact β-dystroglycan at 43 kD is detected in stage 2 and 4 EAE and 
in noninfl  amed brains (Cont.) (A and B). An additional 30-kD β-dystroglycan 
fragment occurs only in EAE glycoprotein enriched and membrane frac-
tions (A and B). Intact α-dystroglycan is observed at  120 kD in all 
  samples (C). Lower bands in C are nonspecifi  c cross-reactivity of the sec-
ondary antibody (D). The  80-kD band represents endogenous IgM μ 
chain, abundant in infl  amed CNS, as shown in the negative control (D).
Figure 4.  MMP-2 and MMP-9 cleave 𝗃-dystroglycan. Western 
blots for β-dystroglycan in glycoprotein-enriched samples from non-
infl  amed brains (Cont.), stage 2 and 4 EAE brains, or Cont. samples treated 
with activated rMMP-2 or rMMP-9 result in the same 30-kD β-dystrogly-
can fragment as seen in EAE samples. Weak reaction of the secondary 
antibody with endogenous Ig as a result of serum infl  ux into diseased 
brains is seen at  50 kD (A). Treatment of the same noninfl  amed sample 
with activated rMMP-1, rMMP-7, rMMP-8, or MMP-3 does not cleave 
β-dystroglycan (B).JEM VOL. 203, April 17, 2006  1013
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β-dystroglycan fragment only in brain extracts of clodronate 
treated mice at day 21 after MOG immunization and of the 
PBS-liposome–treated mice (Fig. 7 C).
Macrophage-derived gelatinases cleave astrocyte 
𝗃-dystroglycan
The in vivo studies suggest that macrophages are the source of 
MMP-2 and MMP-9 in EAE brains, and that these gelatin-
ases may be responsible for the cleavage of astrocyte-derived 
β-dystroglycan. To test this possibility directly, peritoneal 
macrophages and astrocytes were isolated and cultured in 
  vitro. Conditioned medium from macrophage cultures were 
shown by gel zymography to contain pro- and active MMP-2
and MMP-9, whereas astrocyte cultures did not contain 
detectable gelatinase activity (Fig. 8 A). Western blots re-
vealed the identical 43-kD β-dystroglycan molecule on cul-
tured   astrocytes (Fig. 8 B) as observed in noninfl  amed CNS 
extracts (Fig. 8 D), corresponding to the intact molecule. 
Coculture of macrophages and astrocytes or incubation of 
macrophage conditioned medium with astrocyte cultures 
resulted in the 30-kD β-dystroglycan fragment (Fig. 8 B). 
This cleavage was inhibited by MMP inhibitors (TIMP-1 and 
TIMP-4), but not by serine protease or cysteine protease 
  inhibitors (AEBSF, E64, or Aprotinin) (Fig. 8 C). Addition of 
macrophage-conditioned medium to glycoprotein-enriched, 
noninfl  amed CNS extracts was also suffi   cient to result in the 
30-kD β-dystroglycan fragment (Fig. 8 D).
MMP-2/MMP-9 double DK (DKO) mice are resistant to EAE
To investigate the correlation between MMP-2/MMP-9 
  activity, dystroglycan cleavage, and EAE induction, MMP-2 
KO, MMP-9 KO, and MMP-2/MMP-9 DKO mice were 
Figure 5.  Macrophage depletion delays EAE onset. (A) Clodronate-
liposome (Cl Lip) (■)–treated mice are resistant to EAE up to day 21 
after MOG immunization, whereas clinical symptoms appear by day 10 
in PBS-liposome (◆)–treated and untreated mice (●). (B) FACS of CNS 
infi  ltrates reveals that CD45high/MAC3high macrophages represent 32% of 
the total CD45+ population at day 15 after immunization and reduction 
of this population to 13% in Cl Lip–treated mice at day 19. By day 21, the 
proportion of CD45high/MAC3high macrophages increases to 28% in Cl Lip–
treated mice, coincident with EAE onset. Proportions of activated CD45low/
MAC3high microglia do not vary between groups (7.5, 6.9, 7%). Immuno-
fl  uorescence reveals MAC3 positive macrophages in CNS parenchyma of 
PBS-liposome–treated mice at day 15 after immunization that are absent 
in Cl Lip–treated mice until day 19, reappearing at day 21. Images are 
from different mice and represent results from six mice in each group.1014  DYSTROGLYCAN AND GELATINASES IN EAE | Agrawal et al.
used. Adult MMP-9-defi   cient mice have been previously 
shown to have no reduction in the onset or severity of EAE 
symptoms (22), which was confi  rmed here (Fig. 9 A). In 
MMP-2 KO mice used here, both onset of EAE symptoms 
and disease severity did not diff  er from +/− or WT litter-
mates (Fig. 9 A and not depicted). In both MMP-2 KO and 
MMP-9 KO mice, immunofl  uorescence revealed the   occurrence 
of perivascular cuff  s and the loss of dystroglycan immunofl  uo-
rescence at sites of leukocyte infi  ltration, whereas Western blots 
confi  rmed β-dystroglycan cleavage (Fig. 9, B and C). Cellular 
infi  ltrates were normal in both MMP-2 KO and MP-9 KO 
mice and consisted of macrophages, T cells, and DCs (Fig. 9 B). 
MMP-2/MMP-9 DKO mice showed no pro- or active 
forms of MMP-2 or MMP-9 in gel zymography (Fig. 9 A, 
inset). These DKO mice were resistant to EAE up to 40 d 
  after MOG immunization; no CD45+ T cell, macrophage, 
or DC infi   ltration was detected by immunofl  uorescence, 
whereas Western blots confi  rmed the absence of dystroglycan 
cleavage (Fig. 9, B and C). Single or double MMP-2 and 
MMP-9 +/− mice developed disease symptoms at  day 10 
after immunization, similar to WT mice. Treatment of non-
EAE brain tissue with macrophage-conditioned media re-
sulted in cleavage of β-dystroglycan to the 30-kD product 
only when macrophages were derived from WT, MMP-2 
KO, or MMP-9 KO mice, and not from MMP-2/MMP-9 
DKO mice (Fig. 9 D).
D  I  S  C  U  S  S  I  O  N 
Although MMPs have long been implicated in EAE (17), 
this is the fi  rst time that the combined inactivation of the 
gelatinases, MMP-2 and MMP-9, has been shown to be cru-
cial for EAE resistance. Our data clearly show the presence of 
active gelatinases and not collagenases at sites of leukocyte 
infi  ltration, subjacent to the parenchymal BM, and associated 
focal loss of β-dystroglycan immunofl  uorescence. Western 
blot analysis revealed that the loss of β-dystroglycan staining 
was due to the result of its selective cleavage by both MMP-2 
and MMP-9, resulting in a residual 30-kD transmembrane 
fragment and loss of the entire extracellular domain. This 
is the fi  rst identifi  cation of an in vivo MMP-2/MMP-9-
specifi  c substrate and the fi  rst description of selective in situ 
proteolytic damage of a BBB-specifi  c molecule at sites of 
leukocyte infi  ltration.
Leukocyte infi  ltration into the CNS is a multistep process 
involving initial penetration of the endothelial monolayer 
and underlying BM, followed by temporary residency in the 
perivascular cuff   bordered by the endothelial and parenchy-
mal BMs, and fi  nally migration across the parenchymal BM 
and glia limitans into the brain parenchyma. Our novel use of 
in situ zymography coupled with immunofl  uorescent stain-
ing for cellular and extracellular compartments of the in-
fl   amed vessels has allowed precise localization of protease 
activity in EAE. The data demonstrate that gelatinase activity 
Figure 6.  T cells proliferate normally in clodronate-liposome–
treated mice. Antigen-specifi  c (MOG 35–55) (A) and anti-CD3–induced 
T cell proliferation (B) show no signifi  cant difference between clodronate- 
(■ and black bars) or PBS-liposome (◆ and white bars)–treated mice at 
days 15 or 21 after MOG immunization. Data are means ± SEM from 
three experiments with n = 3. Figure 7.  Macrophages are crucial for gelatinase activity and 
𝗃-dystroglycan cleavage. (A) Immunofl  uorescence for CD45 and 
β-dystroglycan in CNS sections of clodronate-treated mice at days 19 
and 21 after MOG immunization and corresponding gelatin in situ zymo-
graphies (ZYM) coupled with staining for CD45 or pan-laminin reveal 
loss of β-dystroglycan staining and gelatinase activity at the parenchy-
mal border (arrows) only in brains of clodronate-liposome–treated mice 
at day 21. (B) Gelatin zymography reveals absence of MMP-2 and MMP-9 
in CNS samples from noninfl  amed (Cont.) and clodronate-liposome–
treated mice at day 19 after immunization, but not in PBS-liposome–
treated mice or clodronate-treated mice at day 21. (C) Corresponding 
Western blots for β-dystroglycan reveal the 30-kD fragment in PBS-lipo-
some–treated mice and clodronate-liposome–treated mice at day 21 after 
immunization, but not at day 19. Images in A are either the same section 
or serial sections and represent results from eight mice in each group. 
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fi  rst becomes detectable in the perivascular space, which is 
the principal site of activity correlating with the sites of leu-
kocyte migration across the parenchymal BM, and not with 
transmigration of the endothelial cell monolayer and its BM.
Gel zymography revealed that MMP-2 and MMP-9 are 
the major proteases active in the infl  amed vessels, consistent 
with previous studies (16, 33), and that macrophages are a 
major source of these gelatinases. Macrophage depletion fol-
lowed by active EAE induction revealed a tight correlation 
between the presence of macrophages and MMP-2 and 
MMP-9 activity and β-dystroglycan cleavage, whereas in 
  vitro studies demonstrated that macrophage-derived MMP-2 
and MMP-9 are suffi   cient for β-dystroglycan cleavage from 
the surface of astrocytes and are also capable of cleaving brain-
derived β-dystroglycan. This strongly suggests that one role 
of macrophages in EAE is to provide active MMP-2 and 
MMP-9, which cleave β-dystroglycan at sites of leukocyte 
penetration of the parenchymal border. It is noteworthy that, 
contrary to our expectations, leukocytes did not accumulate 
in the perivascular cuff   in macrophage-depleted mice, sug-
gesting that macrophages have an additional role before their 
entry into the perivascular cuff   that is independent of their 
proteolytic function. There is evidence that this additional 
role is likely to be antigen presentation (34). In the adoptive 
transfer model, a delay in T cell recruitment into the CNS 
occurs, which has been suggested to be the result of the time 
required for transferred T cells to be primed by recognition 
of CNS antigen in the periphery and then become compe-
tent to enter the brain parenchyma (35). Evidence exists for 
the involvement of both DCs and macrophages in this anti-
gen presentation (34, 36). Our data show that macrophages 
are normally abundant in the leptomeningeal space and in 
perivascular cuff  s in EAE and that clodronate-liposome treat-
ment depletes these macrophage populations without aff  ect-
ing other antigen-presenting cells, such as DCs or activated 
microglia. Clodronate-liposome treatment also did not aff  ect 
T cells or PMN, which were found to accumulate in the lep-
tomeningeal space and in the choroid plexus, but did not 
  infi  ltrate into the brain parenchyma, and T cell proliferation 
studies revealed that there was no major defect at the level of 
T cell activation. Our data, therefore, support an early role 
for macrophages in antigen presentation in EAE and suggest 
that this occurs before entry into the perivascular cuff  , prob-
ably in the leptomeningeal space.
Despite strong gelatinase activity surrounding infl  amed 
vessels, the observed selective cleavage of β-dystroglycan and 
the absence of signifi  cant proteolytic changes in the major 
endothelial or parenchymal BM components (such as lami-
nins, collagen type IV, or agrin) argues against a general di-
gestion of extracellular matrix barriers in EAE. Neurexin, 
a high affi   nity ligand for dystroglycan that occurs between 
neurons and not on the astrocyte endfeet (11), was also not 
  aff  ected, refl  ecting the spatial restriction of the gelatinase 
activity. Our data suggest that gelatinases are essential for 
  selective cleavage events confi  ned to the parenchymal BM–
astrocyte endfeet border, which may lead to local permeability 
changes. This is substantiated by the fact that only localized 
extravasation of serum proteins occurs around infl  ammatory 
lesions and that this change in vessel permeability is a tempo-
rary event. β-dystroglycan is clearly one of the targets of 
this selective gelatinase activity. However, it cannot be ruled 
out that cleavage of BM components close to the amino- or 
carboxy-termini occurs, which may have profound impact 
on BM structure but are not detectable by the methods used 
here. The identifi  cation of such in vivo substrates for gelatin-
ases remains diffi   cult as a result of the temporally and spatially 
restricted action of gelatinases and low levels of cleaved 
  fragments generated, but may become easier in the future 
with the development of novel mass spectrometry–based 
techniques (37).
The identifi  cation of β-dystroglycan as a novel in vivo 
substrate for MMP-2 and MMP-9 in EAE is the fi  rst report 
of a molecular alteration at the BBB associated with sites of 
leukocyte infi  ltration. The only other CNS protein that has 
Figure 8.  Macrophage-derived gelatinases cleave astrocyte and 
brain 𝗃-dystroglycan. (A) Gelatin zymography reveals pro- and active-
MMP-2 and MMP-9 in macrophage-conditioned media (Mϕ), but not in 
astrocyte lysates. (B) Western blots reveal intact β-dystroglycan in astro-
cyte lysates, which is cleaved to the 30-kD fragment by addition of 
  macrophage-conditioned media (Mϕ + astrocyte). (C) Cleavage of astrocyte-
derived β-dystroglycan by macrophage-conditioned media is inhibited by 
MMP inhibitors (TIMP-1, TIMP-4), but not serine and cysteine protease 
inhibitors (AEBSF, E-64, Aprotinin). (D) Incubation of crude CNS extracts 
from healthy mice with macrophage-conditioned media is suffi  cient to 
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been identifi  ed as an in vivo substrate of MMP-9 is NG2 
proteoglycan, which accumulates in the CNS parenchyma as 
a result of demyelination insults, and retards maturation and 
diff  erentiation of oligodendrocytes that are required for re-
myelination (18). Unlike dystroglycan, NG2 does not occur 
at the parenchymal BM-astrocyte endfeet border, but rather 
within the brain parenchyma surrounding oligodendrocytes. 
The dystroglycan complex links the parenchymal BM to the 
cytoskeleton of the astrocyte endfeet and disruptions to these 
interactions, by targeted elimination of dystroglycan (12) or 
changes in its glycosylation, cause severe neuronal defects 
(38). Interestingly, targeted elimination of dystroglycan in the 
CNS results in an infl  ammatory gliosis (12), which is consis-
tent with a role for dystroglycan-mediated interactions as 
barriers to the movement of leukocytes, as suggested by the 
data here.
Cleavage of β-dystroglycan into a 30-kD fragment has 
been previously reported for both tumor and nontransformed 
cells (29, 39, 40) and can be mediated by MMPs, ADAMs, 
serine proteases, or a combination of these proteases, depend-
ing on tissue type (29, 39, 40). A cleavage site has been 
localized to the NH2-terminal extracellular portion of 
β-dystroglycan, resulting in the loss of the α-dystroglycan 
binding domain and retention of a 30-kD COOH-terminal 
fragment anchored within the cell membrane (29, 39). Data 
presented here suggest that the same occurs at the astrocyte 
endfeet. In other tissues, α- and β-dystroglycan have been 
shown to remain nonconvalently associated through the 
binding of the COOH terminus of α-dystroglycan to the 
NH2 terminus of β-dystroglycan even after cleavage (9, 29). 
In EAE brain, Western blots revealed the normal 120-kD 
α-dystroglycan subunit and no larger complexes, indicating that
the cleaved ectodomain of β-dystroglycan is not associated 
with α-dystroglycan and, therefore, probably results in the 
release of α-dystroglycan from the cell surface. As α-dystro-
glycan represents the binding portion of the receptor com-
plex and as astrocyte endfeet are still present at sites where 
dystroglycan is cleaved, this probably results in loss of anchor-
age sites to the parenchymal BM. Whether the released 
α-dystroglycan remains associated with the adjacent BM 
could not be determined as the result of the absence of appro-
priate antibodies. Its potential persistence in the parenchymal 
BM may convey additional signals to the infi  ltrating leuko-
cytes or may alter the structural properties of the parenchymal 
Figure 9.  Combined MMP-2 and MMP-9 activity are crucial for 
EAE. (A) EAE progresses normally in MMP-2 KO (★) and MMP-9 KO (●), 
whereas MMP-2 and MMP-9 DKO (■) mice are resistant to EAE up to 40 d 
after MOG immunization. The inset gel zymograph compares gelatinases 
in CNS extracts from EAE-induced WT, MMP-2 KO, MMP-9 KO, and DKO 
mice. (B) All sections were stained for pan-laminin (green) and either 
CD45, T cell receptor (TCRβ), macrophage/microglia (MAC3), DC (CD11c), 
or β-dystroglycan, revealing normal cellular infi  ltrates and associated 
loss of β-dystroglycan in MMP-2 KO and MMP-9 KO mice (arrows), but 
not in DKO mice. Images are from different specimens and represent re-
sults from eight mice for each of the single KO mice and fi  ve DKO mice. 
(C) Western blot confi  rms the presence of the 30-kD β-dystroglycan frag-
ment in the CNS of WT, MMP-2 KO, and MMP-9 KO, but not DKO mice. 
(D) Incubation of brain extracts from healthy mice (non-EAE) with macro-
phage-conditioned media (Mϕ) from MMP-2 KO, MMP-9 KO, or WT litter-
mates, but not MMP-2/MMP-9 DKO, cleaves β-dystroglycan to the 30-kD 
fragment. Mϕ alone did not contain intact or cleaved β-dystroglycan. 
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BM and thereby alter its stability and/or permeability. In the 
skin, such dystroglycan cleavage processes are physiological 
and probably represent a mechanism for basal keratinocyte 
detachment from the dermal-epidermal BM required for 
their diff  erentiation (29). In contrast, astrocyte endfeet an-
chorage to the parenchymal BM is fi  rm and long-term, and 
only in pathological cases such as infl  ammation is this cleav-
age process induced. It is likely that this MMP-mediated 
cleavage of β-dystroglycan represents a means of honing cell–
matrix interactions required, for example, for cell movement 
or repair processes.
Data presented here indicate that MMP-2 and MMP-9 
have complementary roles in β-dystroglycan cleavage in 
EAE. Our EAE experiments in MMP-9 KO mice are consis-
tent with previous studies (22). However, the absence of 
  diff  erences between MMP-2 KO mice and +/− or WT 
  littermates in the onset of EAE or disease severity contrasts 
with a recent study that reported increased susceptibility to 
EAE (41). A notable diff  erence between the latter study and 
most other EAE studies is the unusually late onset of EAE 
symptoms in the WT mice (day 20) (41), whereas MMP-2 
KO mice show onset of symptoms at  day 10 as reported 
here for both MMP-2 KO mice and their WT littermates. 
We have confi  rmed our fi  ndings on the MMP-2 KO mice in 
WT mice in which MMP-2 activity was eliminated through 
the use of a specifi   c MMP-2 inhibitor (42) (unpublished 
data). As susceptibility to EAE by MOG immunization is 
  infl  uenced by genetic background, this is the most likely ex-
planation for the discrepancy in the data. The absence of 
β-dystroglycan cleavage in the DKO mice, together with the 
clinical changes, indicates that this cleavage is a signifi  cant 
event in leukocyte infi   ltration to the CNS parenchyma. 
However, whether this cleavage is the cause or an eff  ect of 
clinical EAE induction cannot be determined from the data 
present here. Current studies aim at in vivo inhibition of 
β-dystroglycan cleavage via point mutation of the cleavage site
and subsequent EAE susceptibility studies to investigate this 
possibility. Furthermore, the data generated from the DKO 
mice suggest that loss of MMP-2 and MMP-9 has eff  ects in-
dependent of dystroglycan cleavage and before endothelial 
cell transmigration because, as in the macrophage-depleted 
mice, leukocytes did not accumulate in the perivascular space. 
It has been suggested that MMP-9 and MMP-2 aff  ect T cell 
activation in diff  erent manners (43, 44). However, the ab-
sence of signifi  cant changes in EAE onset or severity seen 
here in single KO mice and unpublished data from our labo-
ratory on DKO indicate that this is not a signifi  cant issue in 
the EAE model used. The basis for the absence of a perivas-
cular infi  ltrate in DKO mice is currently being examined.
In conclusion, our results confi  rm that leukocytes use 
  diff  erent mechanisms for penetration of the endothelial cell 
monolayer and BM and the parenchymal BM and glia limi-
tans, with gelatinase activity being required for the latter step. 
We have demonstrated that the activity of MMP-2 or MMP-9 
is essential for EAE induction and have identifi  ed β-dystro-
glycan as a novel in vivo substrate for these gelatinases at the 
BBB. Collectively, the data suggest that gelatinase inhibition 
may protect against damage to the brain parenchyma by ar-
resting the leukocytes infi  ltration.
MATERIALS AND METHODS
Animals
All mice were on a C57BL/6 background. MMP-2 KO mice (N11) were 
from the Institute of Physical and Chemical Research BRC, Japan (45), and 
MMP-9 KO mice (N9) were described previously (22). MMP-2 KO mice 
were bred with MMP-9 KO mice to generate DKO and heterozygous 
  littermate controls. Experiments were conducted according to Animal 
  Welfare guidelines.
MMPs and inhibitors
Inhibitors (Sigma-Aldrich) used were the following: 0.5M 4-(2-aminoethyl)
benzenesulfonly fl  uoride hydrochloride (AEBSF), broad range serine prote-
ase inhibitor; 1 μM aprotinin, general serine protease inhibitor; 10 μM 
trans-epoxysuccinyl-l-leucylamido-(4-guanidino) butane (E-64), general 
cysteine protease inhibitor; and 0.5 mM 1,10-phenanthroline, general 
  metalloproteinase inhibitor. Tissue inhibitors of matrix metalloproteinase 
(TIMP), TIMP-1, and TIMP-4 (R&D Systems) were used as MMP inhibi-
tors that do not aff  ect the activity of ADAMS or TACE. p-Aminophenyl-
mercuric acetate (APMA) (Sigma-Aldrich) was used to activate rMMP-1, 
rMMP-7, and rMMP-8 (R&D Systems).
Experimental protocols
EAE. EAE was induced using the 35–55 peptide of MOG (5). Neurological 
defects were scored as stages 1 (fl  accid tail), 2 (hind limb weakness), 3 (severe 
hind limb weakness), 4 (hind quarter paralysis), and 5 (forelimb weakness). 
CNS samples were collected at diff  erent stages and frozen in Tissue-Tek 
(Sakura Finetek) for immunofl  uorescence and in situ zymography, or snap 
frozen for Western blot and gel zymography.
Macrophage depletion. Liposomes containing clodronate or PBS, a gift 
from Roche Diagnostics GmbH, were injected i.v. (200 μl/mouse) at days 
3, 7, and 9 after MOG immunization (13). Immunofl  uorescence, T cell 
proliferation assays, and FACS analyses were performed at days 10, 15, 19, 
and 21 after immunization.
T cell proliferation assay. T cells were isolated from draining LN, placed 
in RPMI 1640/5% FCS, and β-mercaptoethanol together with splenic DCs 
(from a nonimmunized mouse) and MOG 35–55 (0–100 μg/ml) or anti-
CD3 (0–1 μg/ml), and incubated at 37°C for 3 d. Cell proliferation was 
  determined by [3H]thymidine incorporation.
FACS. Mice were perfused with PBS before spleens, LN, and brains were 
harvested. Spleens and LN were treated with 10 U type II collagenase 
(Roche) and 500 U DNase I (Sigma-Aldrich) and total cells were isolated by 
cell sieving (70 μm). Brain homogenates were separated into neuronal and 
leukocyte populations by discontinuous density gradient centrifugation us-
ing isotonic Percoll (GE Healthcare) (31). FACS was performed using a 
FACS Calibur (Becton Dickinson) with the antibodies indicated in Table I.
Macrophage and astrocyte cultures. Purifi  ed astrocyte cultures were 
generated from cerebral cortices of newborn mice and test cultures stained 
with anti-GFAP (Table I) to ascertain purity.
Mice were injected i.p. with 4% Brewers thioglycollate (Sigma-  Aldrich), 
macrophages were harvested by peritoneal lavage and cultured to confl  uency 
in DMEM-F12/10% FCS.
Gel zymography. Crude CNS extracts were prepared by homogenization in 
ice-cold buff  er (1 M NaH2PO4, 1 M sucrose, 0.5 M EDTA) with protease in-
hibitors (PI; Roche); samples were centrifuged and the solubilized fraction was 
collected. CNS extracts and conditioned media were prepurifi  ed by incubation 
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gels containing 1 mg/ml gelatin under nonreducing conditions. Gels were 
washed in TBS, 25% Triton X-100, followed by TBS, 5 mM CaCl2, 0.02% 
Brij 35 and incubated overnight in the same buff  er. Gels were stained with 
Coomassie blue and destained in acetic acid: methanol: dH2O [10:50:40].
In situ zymography and immunofl  uorescence. MMP activity was lo-
calized in brain sections using a modifi  ed method of Oh et al. (47), which, 
in contrast with classical in situ zymography, does not require separation of 
the substrate from the underlying tissue section, permitting costaining of 
the section and precise cellular localization of MMP activity. 10 μg/ml 
DQ-gelatin or DQ-type IV collagen (EnzCheck; Invitrogen) in 50 mM 
Tris-HCl, pH 7.4, plus 1 mM CaCl2 was applied to CNS cryosections, in 
the presence or absence of 1,10-phenanthroline. Slides were incubated for 6 h 
in a humid chamber at 37°C, washed in PBS, and fi  xed in −20°C methanol 
before immunofl  uorescence staining (5). Digestion of the DQ-gelatin results 
in unquenching of fl  uorochrome, which was detected with excitation at 
460–500 nm and emission at 512–542 nm.
Primary antibodies used in in situ zymography coupled with immuno-
fl  uorescence or immunofl  uorescence alone are listed in Table I. Bound anti-
bodies were visualized using FITC- or Texas red–conjugated goat anti–rat, 
and rhodamine- or Pacifi  c blue–conjugated anti–rabbit secondary antibodies 
(Jackson ImmunoResearch Laboratories and Invitrogen).
Sections were examined using a Zeiss Axiophot microscope equipped 
with epifl  uorescent optics and documented using a Hamamatsu ORCA1 
camera and Openlab software (Improvision).
Western blots: wheat germ agglutinin-glycoprotein extraction. 
Cell/tissue extracts were homogenized in TBS containing 1% Triton X-100 
and PI, and solubilized by rotation at 4°C. KCl-washed membrane fractions 
were prepared from solubilized CNS extracts. Glycoproteins were enriched 
using wheat germ agglutinin (WGA) beads (Vector Laboratories) and used 
in dystroglycan Western blots. In some cases, extracted glycoproteins from 
noninfl  amed CNS or from astrocyte cultures were incubated overnight with 
rMMP-3-activated rMMP-2 or rMMP-9, or with APMA-activated rMMP-1, 
rMMP-7, or rMMP-8, before use in Western blots. Although rMMP-3 
and APMA are both capable of activating rMMP-2 and rMMP-9, MMP-3 
is more effi   cient and was therefore used. rMMP-2 and rMMP-9 activation 
with APMA results in the same pattern of results.
Samples were separated by SDS-PAGE on 3–12% gradient gels, trans-
ferred to PVDF membranes (GE Healthcare), and Western blots were per-
formed using the antibodies indicated in Table I.
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